The Translational Breast Cancer Research Consortium was well represented at the 2025 San Antonio Breast Cancer Symposium (SABCS).  Presentations included:

Molecular causes of subtype switching in primary and metastatic breast tumor pairs from the AURORA US Project [Poster Discussion: PD2-06]  

Molecular characterization of resistance to antibody drug conjugates in metastatic breast cancer: a prospective analysis from the AURORA US Network [Poster Discussion: PD3-09]

Characterizing circulating tumor cell (CTC) enumeration and phenotypic profiling in blood with synchronously obtained tissue in metastatic breast cancer (MBC) in TBCRC / Aurora US [Poster: PS2-07-17]

Peripheral Immune Profiling During Neoadjuvant HER2-Targeted Therapy in HER2-Positive (HER2+) Early Breast Cancer (EBC): Mass Cytometry (CyTOF) Analysis from the MARGOT Trial (TBCRC 052) [Poster: PS2-08-10]

Primary Results from the HR+/HER2- Cohort of TBCRC-053 (P-RAD): A Randomized Trial of No, Low, or High Dose Preoperative RADiation with Pembrolizumab and Chemotherapy in Node-Positive, HER2-Negative Breast Cancer [Oral Presentation: GS2-05]

TBCRC 056: A phase 2 study of neoadjuvant niraparib with dostarlimab for patients with BRCA- or PALB2-mutated breast cancer: results from the TNBC cohort [Oral Presentation: RF5-02]

Immune biomarkers of standard-of-care chemoimmunotherapy response and resistance in real-world patient population: TBCRC 061 [Poster: PS2-07-15]

TBCRC 058: A randomized phase 2 study of enzalutamide, enzalutamide with mifepristone, and treatment of physician’s choice in patients with androgen receptor-positive metastatic triple-negative or estrogen receptor-low breast cancer (NCT06099769) [Poster: PS5-09-04]

QuantifyHER (Trial In Progress): Quantitative Immunofluorescence and/or Messenger RNA to Measure HER2 Expression in Patients With Metastatic Breast Cancer Treated with Trastuzumab Deruxtecan (TBCRC 066) [Poster: PS4-03-12]